Loading
A phase 3 trial of Pevonedistat and Azacitidine in Leukaemia, run by PETHEMA Foundation, active and no longer recruiting.
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy is a phase 3 interventional study registered as NCT04090736 by PETHEMA Foundation, with 302 participants planned, started 2019-09-24 and due to reach its primary completion in 2023-06-30. Interventions recorded: Pevonedistat, Azacitidine. Conditions recorded: Leukemia, Myeloid, Acute.
Linked to the drug Pevonedistat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pevonedistat, Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Azacitidine and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/